带状疱疹重组疫苗（RZV）预防带状疱疹的成本效益：更新的关键评价。
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
机构信息
GSK, Value Evidence, Wavre, Belgium.
GSK, Value Evidence, Singapore, Singapore.
出版信息
Hum Vaccin Immunother. 2023 Dec 31;19(1):2168952. doi: 10.1080/21645515.2023.2168952. Epub 2023 Mar 14.
The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs.
本研究旨在对重组带状疱疹疫苗（RZV）预防带状疱疹（HZ）的成本效益进行批判性评价。于 2017 年 1 月 1 日至 2022 年 2 月 28 日，在 PubMed、Embase 和 Cochrane 中进行了文献回顾，并在选定的公共卫生机构网站上进行了检索，以识别和收集比较 RZV 与带状疱疹活疫苗（ZVL）或不接种疫苗的成本效益研究的数据。收集了研究特征、投入和产出。评估了 RZV 预防 HZ 的总体成本效益。在本综述纳入的 18 项研究中，有 15 项研究表明 RZV 接种预防 HZ 具有成本效益。观察到的增量成本效益比（ICERs）的差异可能与 RZV 保护持续时间的不同假设以及驱动 ICERs 估计的结构和疾病相关研究（模型）输入的不同组合有关。
Zotero 插件